Drug intelligence / Profile preview

89Zr-anti-CD4

Development stage
Unknown
Lead developer
University Medical Center Groningen
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
Administration
Intravenous
01

Overview

89Zr-anti-CD4 is a preclinical zirconium-89 (89Zr)-labeled immuno-positron emission tomography (immunoPET) imaging tracer designed for the non-invasive, in vivo assessment of CD4+ T cells. The tracer is typically prepared by conjugating an anti-CD4 monoclonal antibody (such as the murine clone GK1.5) or its engineered fragments (such as cys-diabodies) with a chelator like deferoxamine (DFO) and radiolabeling it with zirconium-89. It is utilized in preclinical research to visualize and quantify CD4+ T cell infiltration and density in tumors or inflammatory tissues (such as in colitis models) and to evaluate immune responses during immunotherapy, such as PD-L1 checkpoint blockade.

Other names
89Zr-DFO-anti-CD489Zr-GK1.589Zr-GK1.5 FR cDb89Zr-GK1.5 N80D cDb89Zr-GK1.5 cDb89Zr-labeled anti-CD489Zr-labeled anti-CD4 antibodyzirconium-89-labeled anti-CD4zirconium89-labeled anti-CD4zirconium 89-labeled anti-CD4
02

Targets

CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on 89Zr-anti-CD4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-anti-CD4.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call